Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Sarepta Therapeutics, Inc.”

102 pharma patents match "Sarepta Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 102
Index total 30,257
Page 3 / 5

Quick answer

This filtered view shows 102 pharmaceutical patents matching "Sarepta Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

102 results for “Sarepta Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 10344281

    Functionally-modified oligonucleotides and subunits thereof

    Sarepta Therapeutics, Inc. · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted

  2. US 10337003

    Compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted

  3. US 10300149

    Compositions for enhancing transport of molecules into cells

    Sarepta Therapeutics, Inc. · Granted May 28, 2019 · Expires May 23, 2039

    granted

  4. US 10202602

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Sarepta Therapeutics, Inc. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted

  5. US 10144762

    Antibacterial antisense oligonucleotide and method

    Sarepta Therapeutics, Inc. · Granted Dec 4, 2018 · Expires Nov 29, 2038

    granted

  6. US 10106796

    Compound and method for treating myotonic dystrophy

    Sarepta Therapeutics, Inc. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted

  7. US 10076536

    Oligonucleotide analogues targeting human LMNA

    Sarepta Therapeutics, Inc. · Granted Sep 18, 2018 · Expires Sep 13, 2038

    granted

  8. US 10066228

    Oligonucleotides for treating expanded repeat diseases

    Sarepta Therapeutics, Inc. · Granted Sep 4, 2018 · Expires Aug 30, 2038

    granted

  9. US 10006031

    Antisense composition and method for treating muscle atrophy

    Sarepta Therapeutics, Inc. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted

  10. US 9982261

    Antisense antiviral compounds and methods for treating a filovirus infection

    Sarepta Therapeutics, Inc. · Granted May 29, 2018 · Expires May 24, 2038

    granted

  11. US 9944926

    Induced exon inclusion in spinal muscle atrophy

    Sarepta Therapeutics, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted

  12. US 9920085

    Boronic acid conjugates of oligonucleotide analogues

    Sarepta Therapeutics, Inc. · Granted Mar 20, 2018 · Expires Mar 15, 2038

    granted

  13. US 9862946

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Jan 9, 2018 · Expires Jan 4, 2038

    granted

  14. US 9790499

    Functionally-modified oligonucleotides and subunits thereof

    Sarepta Therapeutics, Inc. · Granted Oct 17, 2017 · Expires Oct 12, 2037

    granted

  15. US 9682097

    Oligonucleotide analogues targeting human LMNA

    Sarepta Therapeutics, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted

  16. US 9534220

    Antisense antibacterial method and compound

    Sarepta Therapeutics, Inc. · Granted Jan 3, 2017 · Expires Dec 29, 2036

    granted

  17. US 9506058

    Compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Nov 29, 2016 · Expires Nov 24, 2036

    granted

  18. US 9499583

    Antibacterial antisense oligonucleotide and method

    Sarepta Therapeutics, Inc. · Granted Nov 22, 2016 · Expires Nov 17, 2036

    granted

  19. US 9487786

    Immunosuppression compound and treatment method

    Sarepta Therapeutics, Inc. · Granted Nov 8, 2016 · Expires Nov 3, 2036

    granted

  20. US 9469664

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Sarepta Therapeutics, Inc. · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted

  21. US 9453225

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted

  22. US 9447416

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted

  23. US 9447417

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted

  24. US 9434948

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Sep 6, 2016 · Expires Sep 1, 2036

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.